A new mouse study out of MIT landed on July 15, 2026, and the headlines have been predictably alarming. “Keto causes cancer.” “New study challenges popular theory.” If you’re someone who eats low-carb, you’ve probably already seen these in your feed, and you’re probably wondering whether to panic. I’ll be honest: this study deserves serious attention. It also deserves way more nuance than most coverage has given it.

The researchers, led by Omer Yilmaz at MIT’s Koch Institute, published their findings in Nature on July 15. They fed mice genetically predisposed to intestinal cancer a ketogenic diet and watched what happened. The results split cleanly down anatomical lines. The keto diet suppressed colon tumors. But it accelerated small-intestinal tumor growth, at rates comparable to or even higher than an obesity-inducing diet, even though the keto-fed mice themselves remained lean. That last part is what surprised me most. We’ve long assumed leanness was protective. These mice were lean and still developed more small-intestine tumors.

What surprised me further was the mechanism. Most keto advocates would assume any tumor-promoting effect was about metabolic chaos or blood sugar spikes. It wasn’t. The team identified dietary fat itself as the driver, not ketone bodies. Co-first author Jessica Shay stated plainly that it’s “the high dietary fat content, not the ketone bodies produced during ketosis” that promotes small-intestine tumor growth, according to MIT News. Fat intake appears to cause intestinal stem cells to multiply rapidly, and more active stem cells, as Yilmaz put it, means more chances for something to go wrong genetically. The ketones, specifically BHB (β-hydroxybutyrate), which a landmark 2022 Nature study had suggested were protective against colon cancer, were called “essentially metabolic bystanders” in this context.

Key takeaways
  • The MIT study (Nature, July 15, 2026) found keto accelerated small-intestine tumors in predisposed mice while suppressing colon tumors.
  • Dietary fat drove small-intestine tumor risk, not ketone bodies , BHB was labeled a "metabolic bystander" here.
  • Mice were genetically predisposed to intestinal cancer; findings don't directly apply to healthy humans.
  • Lean keto-fed mice developed small-intestinal tumors at rates comparable to mice on an obesity-inducing diet.
  • Yilmaz explicitly warned against generalizing: "what might be beneficial for one tissue may be detrimental for another."

The Paradox at the Center of This Study

The same diet, in the same animals, had opposite effects on two sections of the gut separated by a few inches. Colon tumors suppressed. Small-intestinal tumors promoted. That’s not a story about keto being good or bad. It’s a story about how blunt our assumptions have been. We’ve treated the gut like a single organ for the purposes of dietary intervention, and this research makes that look naive. The colon and small intestine have different cell populations, different metabolic demands, different stem cell behaviors. A diet that starves one cancer type could be fertilizing another simultaneously.

This paradox also directly challenges the story some in the keto world built around that 2022 Nature paper. BHB protecting the colon was exciting. It fit the narrative. The 2026 study doesn’t erase that colon finding, but it adds a serious asterisk: the same dietary pattern appears to promote stem cell proliferation upstream, in the small intestine, through fat intake rather than ketone production. The mechanism changes everything about how we should interpret both studies.

What “Mouse Study, Genetically Predisposed” Actually Means

Recommended Nutricost Premium MCT Oil Powder

Zero net carb MCT oil powder that mixes into coffee or smoothies to support ketosis and ketogenic diets.

Check Price →

This is where I want to push back on the panic a little, because these caveats genuinely matter. Every animal in this study carried genetic predispositions to intestinal cancer. That’s not a random sample of the population. It’s a model specifically designed to make tumors more likely. Whether the same fat-driven stem cell proliferation mechanism plays out in the same way in healthy humans, over typical keto timeframes, in actual gut tissue, is unknown. Yilmaz himself was direct about this when speaking to reporters, noting “we need to be very careful in generalizing the effects that these diets can have, because what might be beneficial for one tissue may be detrimental for another.”

That said, “it was only mice” is the lazy dismissal, not the honest one. Mouse studies using genetic cancer models have predicted real human biology before. The small intestine is not an organ that gets a lot of cancer screening attention, and small-intestinal adenocarcinoma is rare but real. You don’t want to be cavalier here.

What the Research Landscape Actually Looks Like Right Now

The honest picture is messy. Here’s a side-by-side of what the two key Nature studies found, because they’re being compared constantly and the comparison is usually done sloppily:

StudyPublishedKey FindingMechanism IdentifiedPopulation
BHB & colon cancer (Nature, 2022)2022BHB suppressed colon tumor growthKetone bodies reduced stem cell proliferation in colonMice
Shay, Yilmaz et al. (Nature, 2026)July 15, 2026Keto accelerated small-intestine tumors; suppressed colon tumorsDietary fat increased intestinal stem cell activityGenetically predisposed mice

Neither study tells us what a 45-year-old human eating keto for three years should expect. Both studies tell us that dietary fat and ketone bodies affect intestinal stem cell behavior in ways we didn’t fully understand two years ago, and that the effects are tissue-specific. The research here is genuinely mixed, and anyone claiming certainty in either direction right now is outpacing the evidence.

Practical Thinking for People Currently Eating Keto

I want to be clear: this study is not a reason to immediately abandon a ketogenic diet, especially if it’s managing a condition like type 2 diabetes or epilepsy where the evidence for benefit is much stronger. But there are some honest questions worth sitting with, particularly if you have a personal or family history of gastrointestinal cancers. Discussing this study with a gastroenterologist isn’t overcautious. It’s appropriate.

If you’re doing keto primarily for weight loss and you have no strong metabolic reason to stay strictly ketogenic, this research is a good prompt to consider whether very high fat intake long-term is the only tool available to you. Mediterranean-style low-carb eating, which keeps carbs moderate and fat less extreme, might give you many of the metabolic benefits without the same degree of intestinal stem cell stimulation. That’s speculative on my part, I’ll be honest, because nobody has done that comparison in this context. But the mechanism here is fat intake, not carb restriction per se.

The other practical point: if you’re doing keto and haven’t talked to a doctor about baseline GI health, this is a reasonable moment to do that. Not because this study proves you’re at risk. It doesn’t. But because monitoring makes sense for anyone on a long-term therapeutic diet.

This study is genuinely important, and the science is moving fast enough right now that what we think we know about keto and cancer risk is probably going to look different again in 18 months. Stay curious, stay appropriately skeptical of both the panic and the dismissal, and don’t let anyone, including keto advocates or keto critics, hand you a tidy conclusion that this research doesn’t actually support.

Sources

Photo: Fayette Reynolds M.S. via Pexels

This article is for general informational purposes only and does not constitute medical or dietary advice. Always consult a licensed healthcare provider or registered dietitian before making significant changes to your diet, especially if you have a medical condition.